Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, OncoSec Immunotherapies, Regeneron Pharmaceuticals, and Sanofi Genzyme.

Community Practice Connections™: 17th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Release Date: April 19, 2021
Expiration Date: April 19, 2022

Activity Overview

Though the incidence of skin cancers continues to rise worldwide, significant advances in management and development of novel therapies have contributed to dramatic improvements in patient outcomes. In particular, novel targeted and immunologic therapies have transformed the standard of care for patients with metastatic skin cancers.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 17th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®, held in February 2021. This unique and engaging multimedia activity is ideal for community-based clinicians and focuses on the practical aspects of managing patients with skin cancer, helping clinicians to place recent clinical trial data into the context of patient care. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, OncoSec Immunotherapies, Regeneron Pharmaceuticals, and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists, pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Analyze the use of biomarkers in personalizing care for patients with cutaneous malignancies
  • Assess the latest clinical trial data on current and emerging treatment options for melanoma and other skin-related tumors
  • Develop optimal management protocols for the treatment of melanoma, basal cell carcinoma, squamous cell carcinoma, and other cutaneous malignancies
  • Design best practices for the prevention and mitigation of treatment-associated adverse events in the management of cutaneous malignancies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Faculty

Omid Hamid, MD
Omid Hamid, MD
Chief, Translational Research and Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute, an affiliate of Cedars-Sinai
Director of Experimental Therapeutics
Cedars-Sinai Medical Care Foundation
Los Angeles, CA

Disclosures: Grant/Research Support: Aduro Biotech, Akeso Biopharma, Amgen, Arcus Biosciences, Array BioPharma/Pfizer, BioAtla, Bristol Myers Squibb, CytomX Therapeutics, Exelixis, Genentech, GlaxoSmithKline, Idera Pharmaceuticals, Immunocore, Incyte, Iovance Biotherapeutics, Merck & Co., Moderna, Merck Serono, NextCure, Novartis Pharmaceuticals, Sanofi/Regeneron, Seagen, Torque Pharmaceuticals, Zelluna Immunotherapy; Consultant: Aduro Biotech, Akeso Biopharma, Amgen, Array BioPharma/Pfizer, BeiGene, BioAtla, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Idera Pharmaceuticals, Immunocore, Incyte, Janssen Pharmaceutica, Merck & Co., NextCure, Novartis Pharmaceuticals, Sanofi/Regeneron, Seagen, Tempus, Zelluna Immunotherapy; Speakers’ Bureau: Array BioPharma/Pfizer, Bristol Myers Squibb, Novartis Pharmaceuticals, Sanofi/Regeneron.

Tara C. Mitchell, MD
Tara C. Mitchell, MD
Associate Professor of Medicine
Hematology-Oncology Division
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Research Support: Bristol Myers Squibb, Merck & Co.; Consultant: Bristol Myers Squibb, Merck & Co., OncoSec Medical; Other: Merck & Co. (Scientific Advisory Committee).

Sapna Patel, MD
Sapna Patel, MD
Associate Professor
Director of Uveal Melanoma Program and Online Media
Melanoma Medical
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Sapna Patel has no relevant financial relationships with ineligible companies.

Aleksandar Sekulic, MD, PhD
Aleksandar Sekulic, MD, PhD
Deputy Director, Mayo Clinic Cancer Center
Associate Director, Center for Individualized Medicine
Vice Chair, Department of Dermatology
Chair, Cutaneous Oncology Disease Group
Associate Professor of Dermatology
Mayo Clinic Arizona
Phoenix, AZ

Disclosures: Aleksandar Sekulic has no relevant financial relationships with ineligible companies.

Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD
Deputy Director, Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: NextCure; Consultant: Amgen, Bristol Myers Squibb, Celldex Therapeutics, Genentech, GlaxoSmithKline, Incyte, Merck & Co., Novartis Pharmaceuticals; Shareholder: Biond Biologics, CytomX Therapeutics, ImmuniMax, NexImmune, Protean; Other: Named on a patent held by Moffitt Cancer Center that relates to a predictive marker for ipilimumab; named on a PD-1 biomarker patent by Biodesix.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By